Sermorelin for Adult Growth Hormone Deficiency: Off-Label Use, Dosing, and What Women Need to Know

What Is Sermorelin and Why Is Adult GHD Use Off-Label?

Sermorelin acetate is a synthetic 29-amino-acid analogue of endogenous growth hormone-releasing hormone (GHRH). The FDA approved sermorelin in 1997 exclusively for the treatment of idiopathic growth hormone deficiency in children whose epiphyses have not yet fused. That approval has never been extended to adults.

Adult growth hormone deficiency is a recognized clinical syndrome. The Endocrine Society's 2019 clinical practice guideline defines adult GHD as a condition arising from hypothalamic or pituitary pathology, cranial irradiation, or, rarely, idiopathic causes, and recommends recombinant human GH (rhGH) as the standard of care in confirmed cases. Sermorelin is not mentioned in that guideline as a recommended treatment for adults. Any clinician prescribing it off-label for adult GHD is working outside the bounds of that guidance.

The distinction matters because off-label prescribing carries different liability, different insurance coverage, and a lower evidence floor. You deserve to know that before making a decision.

Why Sermorelin Instead of Recombinant GH?

Recombinant human GH (somatropin) is FDA-approved for adult GHD and covered by most major insurers when diagnosis is confirmed. Sermorelin is typically far less expensive and is available through compounding pharmacies.

Proponents also argue that because sermorelin stimulates the pituitary gland rather than delivering GH directly, the body retains its natural feedback loop, which may reduce the risk of supraphysiologic GH levels. That argument has physiological logic but has not been tested against rhGH in a head-to-head randomized trial in adults.

What the Evidence Actually Shows

The adult sermorelin evidence base is thin but not nonexistent. A placebo-controlled crossover study published in the Journal of Clinical Endocrinology and Metabolism demonstrated that nightly subcutaneous sermorelin in older adults raised IGF-1 levels, improved sleep quality, and increased lean mass over 6 months. A later NIH-funded trial in adults aged 60 to 80 showed that sermorelin (0.5 mg nightly) increased GH pulsatility and IGF-1 without significant adverse metabolic effects over 26 weeks. Both trials were small (fewer than 100 participants) and short. Neither trial enrolled a sufficient proportion of women to allow sex-specific conclusions.

Applying the GRADE framework, the adult GHD evidence for sermorelin sits at Low to Moderate quality: consistent signal, biologically plausible mechanism, but no adequately powered randomized controlled trial in adults with confirmed GHD, no long-term safety data beyond 12 months, and substantial extrapolation from pediatric and older-adult populations.

How Sex-Specific Physiology Changes Everything

GH secretion is not sex-neutral. Women secrete GH in higher amplitude pulses than men across the reproductive years, a pattern driven primarily by estrogen's stimulatory effect on GHRH release and GH secretion at the pituitary. This single fact has cascading clinical implications for how sermorelin works in women at different life stages.

Reproductive Years (Ages Roughly 18 to 40)

During the reproductive years, endogenous GH pulse amplitude is highest in the late follicular and periovulatory phases of the menstrual cycle, when estrogen peaks. Women using combined oral contraceptives show blunted GH pulsatility compared to naturally cycling women, according to data published in JCEM. If you are on hormonal contraception and undergoing sermorelin therapy, your baseline and stimulated GH levels may be lower than expected, which could affect both diagnostic testing and treatment response.

PCOS is worth naming explicitly here. Women with PCOS often have altered GH-IGF-1 axis signaling: some show relative GH hypersecretion alongside insulin resistance, while others have blunted GH responses. A study in Fertility and Sterility found that GH secretion patterns in PCOS differ significantly from those in ovulatory women, which complicates both the diagnosis of GHD and the interpretation of sermorelin stimulation tests in this population.

Perimenopause

The perimenopause stage sees a measurable decline in GH pulse amplitude that parallels falling estrogen. Data from the Study of Women's Health Across the Nation (SWAN) confirm that the transition into menopause is associated with accelerated changes in body composition, including loss of lean mass and increased visceral adiposity, changes that overlap substantially with the phenotype of GHD. This overlap creates diagnostic ambiguity: perimenopausal symptoms and adult GHD share so many features that distinguishing them without provocative GH testing is clinically unreliable.

Sermorelin stimulation testing in perimenopausal women may yield lower peak GH responses not because of true GHD but because of estrogen deficiency. This is not a theoretical concern. The Endocrine Society guideline notes that sex steroid priming before GH stimulation testing is sometimes used in women to avoid false-positive GHD diagnoses. Whether the same principle applies to sermorelin as a stimulation agent in perimenopausal women has not been formally studied.

Post-Menopause

After menopause, GH secretion continues to decline. Postmenopausal women on systemic estrogen therapy (ET) show higher GH secretion and IGF-1 levels than those not on ET. A trial published in JCEM found that oral estrogen actually reduced IGF-1 despite raising GH, because oral estrogen undergoes first-pass hepatic metabolism that impairs IGF-1 synthesis. Transdermal estrogen does not produce this paradox. If you are postmenopausal and on oral ET while also receiving sermorelin, your IGF-1 may underestimate your true GH response, which matters for dosing decisions.

Off-Label Dosing Protocols Used in Practice

No FDA-approved adult dosing protocol for sermorelin exists. What follows describes the protocols used in practice and studied in the available literature. This is not a prescription.

Starting Dose and Titration

Most off-label protocols in adults start at 0.2 mg (200 mcg) subcutaneously at bedtime, timed to coincide with the circadian peak in endogenous GH secretion. Some clinicians titrate up to 0.3 mg based on IGF-1 response at 4 to 6 weeks.

Women generally require lower doses than men to achieve equivalent IGF-1 targets, consistent with the sex difference in GH sensitivity. Starting at the lower end of any published range is sensible for women, though no randomized dose-finding trial in women specifically has been conducted. This is an evidence gap.

Route and Timing

Sermorelin is given by subcutaneous injection, typically into the abdomen or thigh, rotating sites. Evening administration is preferred because GH release is highest during slow-wave sleep. Oral bioavailability is negligible due to peptide degradation.

Monitoring Parameters

Clinicians prescribing sermorelin off-label typically monitor:

• IGF-1 levels at baseline, 4 to 6 weeks, and every 3 months thereafter
• Fasting glucose and HbA1c, because GH raises insulin resistance acutely
• Thyroid function (TSH, free T4), because GH can unmask central hypothyroidism
• Blood pressure, fluid retention symptoms, and carpal tunnel symptoms

The Endocrine Society guideline for rhGH in adult GHD targets IGF-1 in the midnormal range for age and sex. The same target is commonly applied to sermorelin therapy, though this is by extrapolation.

How Long Do People Use It?

Published trials ran for 6 to 26 weeks. Long-term safety data beyond 12 months do not exist in adults. Many off-label users continue indefinitely, which means they are accepting unknown long-term risk. The compounding pharmacy source adds a regulatory layer: compounded sermorelin is not FDA-inspected for potency or sterility in the same way that approved drugs are.

The WomanRx Life-Stage Dosing Framework for Off-Label Sermorelin pulls together the evidence gaps above into a single clinical decision structure. Before starting sermorelin, a woman should be categorized by:

1. Hormonal status (reproductive, perimenopausal, postmenopausal, surgically menopausal)
2. Estrogen therapy type if applicable (oral vs. Transdermal, because of the IGF-1 interpretation issue)
3. Presence of PCOS, hypothyroidism, or other GH-axis modifying conditions
4. Contraception status (sermorelin is contraindicated in pregnancy; confirmed reliable contraception is required in women of reproductive age before starting)

Each category changes how you interpret baseline IGF-1, how you define a target, and what the most likely side effects are. No published protocol incorporates all four variables. This framework is offered as a clinical reasoning tool, not as a substitute for individualized care.

Pregnancy, Lactation, and Contraception

Sermorelin is contraindicated in pregnancy. There are no adequate, well-controlled studies in pregnant women. Animal reproduction studies are not available in sufficient detail to rule out fetal harm. Because GH-axis peptides cross the placenta to some extent and fetal GH regulation is distinct from adult regulation, the precautionary principle applies.

If you are of reproductive age and a clinician recommends sermorelin, you must be using reliable contraception. This means methods with a failure rate below 1% with typical use: an intrauterine device (IUD, hormonal or copper), a subdermal implant, or sterilization. Barrier methods alone are not considered sufficient for teratogen-risk medications. Combined oral contraceptives are an option for contraception, but note the effect on GH pulsatility described above, which may affect your response to sermorelin.

If you become pregnant while taking sermorelin, discontinue immediately and contact your clinician.

Lactation: It is not known whether sermorelin or its metabolites are excreted into human breast milk. Because peptide drugs are generally digested in the infant GI tract, systemic absorption by a breastfed infant may be low, but this has not been studied. The absence of data is not reassurance. The recommendation is to avoid sermorelin during breastfeeding.

The FDA Drugs in Pregnancy and Lactation resource does not include a specific sermorelin lactation entry, reinforcing that this is an evidence-free zone.

Who This Is Right For, and Who It Is Not

Women Who May Be Reasonable Candidates

• Women with confirmed adult GHD by provocative testing (insulin tolerance test or glucagon stimulation test), who cannot afford or access FDA-approved rhGH, or who prefer a pituitary-stimulating approach
• Postmenopausal women on transdermal estrogen therapy who have documented low IGF-1 after ruling out oral-estrogen suppression as the cause
• Women with a history of childhood-onset GHD transitioning to adult care, in consultation with a pituitary endocrinologist

Women for Whom Off-Label Sermorelin Is Not Appropriate

• Women who are pregnant, trying to conceive, or breastfeeding (absolute contraindication)
• Women with active malignancy or a history of GH-sensitive tumors, because GH and IGF-1 are mitogenic
• Women with untreated hypothyroidism (GH therapy will worsen it, and sermorelin should not be started until thyroid status is optimized)
• Women with known hypersensitivity to GHRH or sermorelin
• Women with type 2 diabetes that is poorly controlled, given GH's insulin-antagonizing effect
• Women with active intracranial lesions, because GHRH stimulation in this context carries unknown risk

Endometriosis and fibroids deserve a specific note. GH and IGF-1 have been implicated in the proliferation of endometriotic lesions and uterine fibroids in preclinical models. A review in Fertility and Sterility discussed the role of the GH-IGF-1 axis in endometrial and uterine tissue growth. Clinical evidence is insufficient to call this a firm contraindication, but it is a conversation you should have with your clinician before proceeding if either condition applies to you.

Conditions That Overlap With Adult GHD in Women

Several conditions common in women produce symptoms that closely mimic adult GHD. Recognizing them matters because sermorelin will not help if the underlying problem is something else.

Hypothyroidism: Fatigue, weight gain, cognitive slowing, and poor exercise tolerance are features of both GHD and hypothyroidism. Postpartum thyroiditis affects up to 10% of women in the first year after delivery and can be missed. Always exclude thyroid disease before attributing symptoms to GHD.

Perimenopause and menopause: As noted above, the phenotypic overlap with GHD is so substantial that symptoms alone cannot separate them. Serum IGF-1 and provocative testing are required.

PCOS-related metabolic dysfunction: Insulin resistance, altered body composition, fatigue, and irregular cycles in PCOS can be misread as GHD features. The GH-IGF-1 axis is already dysregulated in PCOS, making interpretation more complex.

Female pattern hair loss and hormonal acne are not features of classic GHD, but they are sometimes attributed to GH axis abnormalities in marketing for off-label sermorelin. The evidence for sermorelin improving either condition is anecdotal and should be treated with skepticism.

Side Effects and Risks Specific to Women

Common side effects reported in clinical trials include injection site reactions, flushing, and headache. These are generally mild and transient.

More significant risks include:

• Fluid retention and edema. GH increases renal sodium reabsorption. Women already prone to cyclical fluid retention may notice worsening premenstrually.
• Insulin resistance. GH acutely antagonizes insulin action. Women with PCOS, prediabetes, or gestational diabetes history need closer glucose monitoring.
• Carpal tunnel syndrome. Reported with rhGH therapy and plausible with sermorelin-induced GH elevation.
• IGF-1 excess. If IGF-1 rises above the age-adjusted normal range, dose reduction or discontinuation is indicated. Supraphysiologic IGF-1 is associated with increased cancer risk in epidemiologic studies, including a large meta-analysis in The Lancet Oncology finding associations between circulating IGF-1 and breast, colorectal, and prostate cancer risk.

Women with a personal or strong family history of hormone-sensitive breast cancer should discuss the IGF-1 and cancer risk evidence in detail with their oncologist before considering sermorelin.

What Confirmed Adult GHD Diagnosis Actually Requires

Off-label use of sermorelin is not appropriate as a diagnostic tool for adult GHD. Diagnosis requires:

1. Clinical suspicion based on hypothalamic or pituitary disease, irradiation history, or prior childhood GHD
2. Low serum IGF-1 for age and sex on at least one measurement
3. Confirmed low peak GH response on a provocative test: the insulin tolerance test (ITT) remains the gold standard (peak GH <3 ng/mL in most guidelines), or glucagon stimulation if ITT is contraindicated
4. At least one other pituitary hormone deficiency, or structural pituitary disease, increases pre-test probability substantially

The Endocrine Society guideline specifies that GH stimulation testing is mandatory before starting adult GHD treatment, except in patients with three or more other pituitary hormone deficiencies and a low IGF-1. Treating based on symptoms and low-normal IGF-1 alone, without provocative testing, is not appropriate.

Accessing Sermorelin: Compounding Pharmacies and Regulatory Realities

FDA-approved sermorelin (Geref) was discontinued from the US market. All sermorelin currently prescribed for adults in the United States comes from compounding pharmacies operating under Section 503A or 503B of the Food, Drug, and Cosmetic Act. Compounded drugs are not FDA-approved for safety, efficacy, or potency. The FDA has issued guidance clarifying that compounded versions of discontinued drugs occupy a legally complex space.

This means the sermorelin you receive from a compounding pharmacy may not be identical in potency or purity to what was studied in published trials. Ask your compounding pharmacy for a Certificate of Analysis for each batch, and confirm they are licensed by your state board of pharmacy and, ideally, accredited by the Pharmacy Compounding Accreditation Board (PCAB).

The FDA has taken enforcement action against certain compounded peptide preparations, and the regulatory field for peptide compounding is actively changing. Confirm current legal availability with your prescribing clinician before starting.